Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Hepatic Encephalopathy in Hepatitis C Cirrhosis
NCT00281502Phase 2Unknown
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2005
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaximin in hepatic encephalopathy (HE), sponsored by Weill Cornell Medicine. Status: unknown.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT00281502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281502.